Efficacy of peginterferon α-2a and predictors of response in HBeAg-negative, genotype D-naive patients
暂无分享,去创建一个
F. Sanai | A. Abdo | Mohammed Q. Khan | K. Bzeizi | H. Al-Ashgar | A. Aljumah | Mosa A. Fagih | M. Dafalla
[1] Jia-Horng Kao,et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.
[2] H. Chan,et al. Predictors of Treatment Response in Chronic Hepatitis B , 2009, Drugs.
[3] P. Komolmit,et al. Comparison between quantitative hepatitis B surface antigen, hepatitis B e‐antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon‐α‐2b therapy in hepatitis B e‐antigen‐positive chronic hepatitis B , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.
[4] E. Steyerberg,et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. , 2009, Gastroenterology.
[5] L. Demelia,et al. A randomized controlled trial of pegylated interferon-α2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B , 2009, Antiviral therapy.
[6] P. Komolmit,et al. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[7] T. Asselah,et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. , 2009, Journal of hepatology.
[8] P. Marcellin,et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. , 2009, Gastroenterology.
[9] T. Asselah,et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients , 2009, Hepatology.
[10] P. Marcellin,et al. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B , 2009, Hepatology.
[11] F. Ansaldi,et al. Influence of body mass index, cholesterol, triglycerides and steatosis on pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C in patients transplanted for HCV and alcoholic cirrhosis. , 2009, Hepato-gastroenterology.
[12] V. Wong,et al. A review of the natural history of chronic hepatitis B in the era of transient elastography , 2008, Antiviral therapy.
[13] Jörg Petersen,et al. EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.
[14] K. Simon,et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. , 2008, Gastroenterology.
[15] Y. Liaw,et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update , 2008, Hepatology international.
[16] K. Yuen,et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. , 2008, Journal of hepatology.
[17] G. Lau,et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B , 2008, Hepatology international.
[18] R. Gish,et al. A Pilot Study of Extended Duration Peginterferon Alfa-2a for Patients With Hepatitis B e Antigen-Negative Chronic Hepatitis B , 2007, The American Journal of Gastroenterology.
[19] P. Marcellin,et al. Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B , 2006, Gut.
[20] Olga Angelopoulou,et al. Prediction of Treatment-Related HBsAg Loss in HBeAg-Negative Chronic Hepatitis B: A Clue from Serum HBsAg Levels , 2007, Antiviral therapy.
[21] F. Sanai,et al. Hepatitis B genotypes: relation to clinical outcome in patients with chronic hepatitis B in Saudi Arabia. , 2006, World journal of gastroenterology.
[22] H. Janssen,et al. Successful Treatment with Peginterferon alfa-2b of HBeAg-positive HBV Non-Responders to Standard Interferon or Lamivudine , 2006, The American Journal of Gastroenterology.
[23] D. Blondin,et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D , 2005, Gut.
[24] D. Blondin,et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. , 2005, Gut.
[25] G. Gerken,et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.
[26] P. Marcellin,et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.
[27] C. Gibbs,et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.
[28] D. Lavanchy,et al. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.
[29] J. Rodés,et al. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. , 2002, Gastroenterology.
[30] S. Hadziyannis,et al. The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B , 2001 .
[31] S. Hadziyannis,et al. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. , 2001, Journal of hepatology.
[32] M. Brunetto,et al. Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. , 1995, Journal of hepatology.
[33] M. Brunetto,et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. , 1993, Gastroenterology.
[34] A. Detsky,et al. Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.
[35] I. Lauder,et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. , 1992, Gastroenterology.
[36] M. Milella,et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. , 1992, Journal of hepatology.
[37] E. Schiff,et al. A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B , 1990 .
[38] E. Schiff,et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. , 1990, The New England journal of medicine.
[39] A. Makris,et al. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. , 1990, Journal of hepatology.